No Detail Found!

Effects of a Combination Therapy of Sclerostin Antibody III and Raloxifene on Bone Formation Markers in Ovariectomized Rats.

Author(s)
Hayam Ibrahim Gad Allam Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
Abstract
Objective: To determine the systemic effect of sclerostin monoclonal antibody (Scl-AbIII) administration on markers of bone formation and compare it with a combination of sclerostin antibody and raloxifene. Study Design: Experimental study. Place and Duration of Study: Medical College Animal House at King Khaled University Hospital, Riyadh, Saudi Arabia, from January to November 2014. Methodology: Forty-five female rats were divided into 5 groups equally; 1 control group and 4 groups of ovariectomized (OVX) rats: control OVX rats and OVX rats treated by Scl-AbIII, raloxifene or Scl-AbIII+raloxifene one month after ovariectomy, continued for 4 weeks. At the end of treatment, serum levels of Bone Specific Alkaline Phosphatase (BSAP), alkaline phosphatase, osteocalcin, Insulin-like Growth Factor-1 (IGF-1), Parathyroid Hormone (PTH), Ca2+ and phosphorus were measured. Uterus was weighed and body weight change was calculated. Results: Scl-AbIII or raloxifene treatment produced significant increase of serum BSAP, osteocalcin, IGF-1, PTH and Ca2+ levels. Raloxifene, either alone or combined with Scl-AbIII attenuated the decrease in uterus wet weight, and the increase in body weight seen in OVX rats. Combination therapy of Scl-AbIII, and raloxifene produced significant increase of serum alkaline phosphatase, osteocalcin and IGF-1 levels than treatment with either Scl-AbIII or raloxifene alone. Conclusion: Combination therapy of Scl-AbIII and raloxifene is an attractive strategy to enhance bone formation and can offer better gain over treatment with either one of them alone. Confirmation of these preliminary observations must await careful long-term studies.
Publication Details
Page(s) 46-50
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 26, Issue: 1, Year: 2016

Request the full text from PASTIC

References
IshtiaqS,FogelmanI,HampsonG, 2015.Treatment of postmenopausal osteoporosis: beyond bisphosphonates,J Endocr Invest 38 13 -29
CairoliE,ZhukouskayaV,Eller-VainicherC,ChiodiniI., 2015.Perspectives on osteoporosis therapies,J Endocr Invest 38 303 -11
LeuchtP,HelmsJA, 2015.Wnt signaling: An emerging target for bone regeneration,J Am Acad Orthop Surg 23 67 -68
ZhaoR, 2012.Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective,Int J Med Sci 9 825 -
GennariL,MerlottiD,NutiR, 2010.Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene,Clin Interv Aging 5 19 -29
LiX,OminskyMS,WarmingtonKS,MoronyS,GongJ,CaoJ, 2009.Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis,J Bone Miner Res 24 578 -88
BlackLJ,SatoM,RowleyE,MageeD,BekeleA,WilliamsD, 1994.Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats,J Clin Invest 93 63 -
OminskyMS,VlasserosF,JoletteJ,SmithSY,StouchB,DoellgastG, 2010.Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength,J Bone Miner Res 25 948 -59
FolwarcznaJ,Kaczmarczyk-SedlakI,PytlikM,NowinskaB,CegielaU,SliwinskiL, 2009.Effect of low-dose tacrolimus coadministered with raloxifene on the skeletal system in male rats,Acta Poloniae Pharmaceutica 66 207 -12
CaoZT,SwiftTA,WestCA,RosanoTG,RejR, 2004.Immunoassay of estradiol: unanticipated suppression by unconjugated estriol,Clin Chem 50 160 -5
AzingeEC,BolarinDM, 2006.Osteocalcin and bone-specific alkaline phosphatase in sickle cell haemoglobinopathies,Niger J Physiol Sci 21 21 -5
ScarianoJK,GarryPJ,MontoyaGD,ChandaniAK,WilsonJM,Baumgartner RN, .Serum leptin levels, bone mineral density, -
TschuorF,ZiniE,SchellenbergS,WengerM,BorettiFS,ReuschCE, 2012.Evaluation of four methods used to measure plasma insulin-like growth factor 1 concentrations in healthy cats and cats with diabetes mellitus or other diseases,Am J Vet Res 73 1925 -31
FindlayJW,DillardRF, 2007.Appropriate calibration curve fitting in ligand binding assays,AAPS J 9 E260 -7
BurtisCA,AshwoodER,BrunsDE, 2012.,Tietz Textbook of Clinical Chemistry and Molecular Diagnostics 1739 -51
LinC,JiangX,DaiZ,GuoX,WengT,WangJ, 2009.Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling,J Bone Miner Res 24 1651 -61
PadhiD,JangG,StouchB,FangL,PosvarE, 2011.Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody,J Bone Miner Res 26 19 -26
TasciA,BilgiliH,AltunayH,GecitM,KeskinD., 2011.Prospective evaluation of Vitamin K2, Raloxifene and their coadministration in osteoporotic rats,Eur J Pharm Sci 43 270 -7
LiC,OminskyMS,TanHL,BarreroM,NiuQT,AsuncionFJ, 2011.Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene,Bone 49 1178 -85
AlaeeF,VirkMS,TangH,SugiyamaO,AdamsDJ,StolinaM, 2014.Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model,J Orthop Res 32 197 -203
TianX,JeeWS,LiX,PasztyC,KeHZ, 2011.Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model,Bone 48 197 -201
SinderBP,SalemiJD,OminskyMS,CairdMS,MariniJC,KozloffKM, 2015.Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment,Bone 71 115 -23
BukataSV, 2011.Systemic administration of pharmacological agents and bone repair: what can we expect,Injury 42 605 -8
TakedaS,SakaiS,ShiraishiA,KoikeN,MiharaM,EndoK., 2013.Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats,Bone 53 167 -73
PeanoBJ,CrabtreeJS,KommBS,WinnekerRC,HarrisHA, 2009.Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland,Endocrinology 150 1897 -903
0

Citations

0

Downloads

112

Views